UCB SA (UCBJF)
236.94
+1.50
(+0.64%)
USD |
OTCM |
Oct 06, 16:00
UCB Price to Book Value
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 7.319 |
| September 18, 2026 | 7.840 |
| September 17, 2026 | 7.734 |
| September 16, 2026 | 7.764 |
| September 15, 2026 | 7.842 |
| September 14, 2026 | 7.889 |
| September 11, 2026 | 7.703 |
| September 10, 2026 | 7.252 |
| September 09, 2026 | 7.712 |
| September 08, 2026 | 7.866 |
| September 04, 2026 | 7.991 |
| September 03, 2026 | 7.780 |
| September 02, 2026 | 8.265 |
| September 01, 2026 | 7.891 |
| August 31, 2026 | 7.851 |
| August 28, 2026 | 7.851 |
| August 27, 2026 | 8.374 |
| August 26, 2026 | 8.343 |
| August 25, 2026 | 8.366 |
| August 24, 2026 | 8.366 |
| August 21, 2026 | 8.233 |
| August 20, 2026 | 8.108 |
| August 19, 2026 | 8.178 |
| August 18, 2026 | 7.967 |
| August 17, 2026 | 7.967 |
| Date | Value |
|---|---|
| August 14, 2026 | 7.967 |
| August 13, 2026 | 8.233 |
| August 12, 2026 | 8.178 |
| August 11, 2026 | 8.274 |
| August 10, 2026 | 8.327 |
| August 07, 2026 | 8.429 |
| August 06, 2026 | 8.444 |
| August 05, 2026 | 8.444 |
| August 04, 2026 | 8.089 |
| August 03, 2026 | 8.257 |
| July 31, 2026 | 8.439 |
| July 30, 2026 | 8.124 |
| July 29, 2026 | 9.250 |
| July 28, 2026 | 8.778 |
| July 27, 2026 | 9.008 |
| July 24, 2026 | 9.094 |
| July 23, 2026 | 8.682 |
| July 22, 2026 | 8.682 |
| July 21, 2026 | 8.682 |
| July 20, 2026 | 8.889 |
| July 17, 2026 | 8.551 |
| July 16, 2026 | 8.750 |
| July 15, 2026 | 8.617 |
| July 14, 2026 | 8.502 |
| July 13, 2026 | 8.742 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Johnson & Johnson | 7.353 |
| Eli Lilly & Co. | 33.15 |
| Novo Nordisk A/S | 4.989 |
| Pfizer Inc. | 1.876 |
| Teva Pharmaceutical Industries Ltd. | 5.863 |
Price to Book Value Related Metrics
| PE Ratio | 17.97 |
| PS Ratio | 4.625 |
| PEG Ratio | 0.0201 |
| Price to Free Cash Flow | 32.67 |
| Price | 236.94 |
| Earnings Yield | 5.57% |
| Market Cap | 45.18B |
| PEGY Ratio | 0.0201 |
| Operating PE Ratio | 14.53 |
| Normalized PE Ratio | 17.81 |